▶주메뉴 바로가기
▶본문 바로가기
[THE INVESTOR] Korea’s biotech firm BotaMedi said on May 11 it has attracted funds worth 170 billion won (US$159 million) from a Chinese company to bring its sea-based antioxidant products to China....
[THE INVESTOR] Investors are seeking to take legal action against Samsung BioLogics after the firm lost a whopping 8 trillion won (US$7.43 billion) in market cap in a week, hit by profit-paddling al...
[THE INVESTOR] Amorepacific, Korea’s leading cosmetics maker, said on May 9 its first-quarter net profit declined 20.9 percent from the previous year. Net income came to 176.7 billion won (US$16...
[THE INVESTOR] Celltrion posted a 24 percent jump in first-quarter net profit on May 9, boosted by its biosimilar products that further penetrated the US and European markets. Net profit came in at...
[THE INVESTOR] Korea’s financial regulator is likely to decide the fate of Samsung BioLogics on May 23 at the earliest over allegations that the company had doctored its accounting books. The natio...
[THE INVESTOR] Samsung BioLogics has come under pressure as the country’s financial authorities have claimed that the evaluation of its affiliate violated accounting rules. Dubbed as one of Samsung...
[THE INVESTOR] An affiliate of Korean biopharmaceutical firm Celltrion said on May 3 that its breast cancer biosimilar has begun selling in Britain following approval from Europe’s regulatory body. ...
[THE INVESTOR] Samsung BioLogics said on May 2 that it would consider filing an administrative lawsuit against the country’s financial authorities if they conclude that it intentionally manipulated ...
[THE INVESTOR] Inflectra, Celltrion’s version of Johnson & Johnson’s Remicade, posted robust US sales growth in the first quarter, according to its distribution partner Pfizer’s financial report o...
[THE INVESTOR] The Financial Supervisory Service on May 1 concluded that Samsung BioLogics inflated its net profit for the fiscal year of 2015, just a year before its public listing on the country’s...
[THE INVESTOR] Huons said on April 30 that it has signed a contract worth 56.7 billion won (US$53.10 million) with Spanish dermo-cosmetics brand Sesderma to supply its self-developed botulinum toxin...
[THE INVESTOR] Chong Kun Dang Pharmaceutical said on April 27 it has been granted a patent covering the manufacturing process of its version of Kyowa Hakko Kirin and Amgen’s anemia drug Aranesp fro...
[THE INVESTOR] Korea’s pharmaceutical giant Celltrion has become a strong competitor to European and US drugs with its biosimilars, indicated by changes in sales, industry officials said on April 27...
[THE INVESTOR] Biogen has confirmed that it will make an additional investment worth 400 billion won (US$370 million) in Samsung Bioepis, a biosimilar developer and a joint venture between Samsung B...
[THE INVESTOR] LG Household & Health Care said on April 24 its affiliate will purchase a Japanese cosmetics firm for 10.5 billion yen (US$97.60 million) to expand its overseas business. Ginza St...
Why birth order is a big deal at LG
JB Financial’s Phnom Penh Commercial Bank expands on upbeat earnings
Line becomes largest shareholder of Taiwan’s iPass
Kakao sets up holding firm to control blockchain units
Samsung BioLogics makes another appeal to ward off fraud accusations
Park Hyeon-joo steps down as Mirae Asset Daewoo chairman
Esmo denies merger talks with Samsung
Samsung BioLogics gets FDA nod for 2nd plant
May 27, 2018
